HOME >> MEDICINE >> NEWS
ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia

ausing bone marrow dysfunction and enlargement of the lymph nodes, liver and spleen. Standard front line therapy consists of alkylating agent based drug regimens. Fludarabine is the only approved drug for the treatment of patients who have failed alkylating agents. No approved therapy is available for patients who fail fludarabine therapy.

CAMPATH appears to work in CLL by depleting malignant CLL cells, which bear the CD52 antigen. CAMPATH is a humanized monoclonal antibody which is directed against the CD52 antigen found on normal and malignant lymphocytes, on normal macrophages and monocytes, but has not been detected on hematopoietic stem cells.

CAMPATH therapy is associated with significant lymphopenia. The lymphopenia resolves in some, but not all, patients over weeks to months after cessation of CAMPATH therapy.

"Early studies suggested the promise of CAMPATH. This study appears to confirm the decision to submit a BLA to the FDA," said Kanti R. Rai, M.D., Chief, Division Hematology-Oncology, Long Island Jewish Medical Center. "CAMPATH may very well become the next new and promising monoclonal antibody therapy for patients with cancer. For our patients with CLL, CAMPATH may change the expectation from one of relentlessly progressive deterioration on palliative therapies to the hope of extended survival," said Dr. Rai, who is also one of the trial's principal investigators and an internationally recognized expert in CLL.

ILEX and LeukoSite are developing CAMPATH through a joint venture that was established in May 1997. Clinical trials in the treatment of non-Hodgkin?s lymphoma, CLL, and other malignancies expressing CD52 are being planned.

"CAMPATH is the most advanced of ILEX's nine compounds and we are anxious to make it available to patients," said Richard L. Love, president and chief executive officer of ILEX.

ILEX Oncology, Inc. is a drug development company focused exclusively on accelerated development of drugs fo
'"/>

Contact: Deborah Sibley, ILEX Oncology
210-949-8287
Porter Novelli
12-Jun-1999


Page: 1 2 3 4 5

Related medicine news :

1. The 23rd Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO)
2. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
3. The Lancet Oncology (TLO)
4. The Lancet Oncology press release
5. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)
6. The Lancet Oncology (TLO) June 2002
7. The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)
8. The Lancet Oncology and The Lancet Infectious Diseases
9. V. Craig Jordan Will Present Results Of Raloxifene Breast Cancer Study At American Society For Clinical Oncology Meeting
10. First UK cases of previously rare disease reported in gay men
11. Health care report cards may increase racial/ethnic disparities in bypass operations

Post Your Comments:
(Date:5/24/2015)... 24, 2015 Women’s Excellence ... pressure measurements in patients’ bladder and urethra. This provides ... it if they have reported symptoms of stress urinary ... Women’s Excellence in Bladder Control is a comprehensive center ... or problems with overall control of their bladder. The ...
(Date:5/24/2015)... 24, 2015 Indiana Fiber Network, LLC ... Midwest Telecom of America, Inc. (MTA) has selected IFN ... Cory Childs, IFN Enterprise Sales Manager, fiber route diversity ... “IFN’s fiber transport provides MTA with the diverse fiber ... Tier 1 Internet and voice carriers located at Henry ...
(Date:5/23/2015)... D.C. (PRWEB) May 23, 2015 On ... of powers of a youngster's yogic power learned through ... Sri Nithyananda Swami in Bangalore, India. , Yogamaatha, a ... more than 50 high profile professionals attending the 2015 ... by reading fluently -- blindfolded. , In a ...
(Date:5/23/2015)... (PRWEB) May 23, 2015 Manufacturers are now ... Performance Factor (HSPF) of 8.2. Experts in the field agree ... benefit consumers. , The HSPF score is what miles per ... more efficient the unit. Although the minimum HSPF score has ... heaters with an HSPF score north of 12. Indeed, the ...
(Date:5/22/2015)... Pasadena, Calif. (PRWEB) May 22, 2015 ... where technology, communication and capacity are intersecting to ... and across society, the opening speaker at WesternU's ... , California Lieut. Gov. Gavin Newsom, a former ... was the keynote speaker at the graduation ceremony ...
Breaking Medicine News(10 mins):Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3
(Date:5/22/2015)... 22, 2015 The North American dental ... is estimated to reach $90.7 million by 2019, at a ... through the TOC of North America Dental Lasers Market for ... of various tables and figures. http://www.micromarketmonitor.com/market/north-america-dental-lasers-1771208223.html ... this report.   Dental lasers are specifically ...
(Date:5/22/2015)... -- The Mesothelioma Victims Center is incredibly passionate about ... best possible compensation, and they are also extremely focused ... caused by exposure to asbestos or their family ... options such as a recent possible medical breakthrough. For ... anytime at 866-714-6466. http://MesotheliomaVictimsCenter.Com ...
(Date:5/22/2015)... 22, 2015 Today, Rhodes Pharmaceuticals L.P. announced ... stimulant indicated for the treatment of Attention-Deficit/Hyperactivity Disorder ... 2015. The announcement comes just ... the U.S. Food and Drug Administration (FDA). ... of methylphenidate capsule with an onset of effect ...
Breaking Medicine Technology:North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6
Cached News: